|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,527,813: Scope, Claims, and Patent Landscape
What does U.S. Patent 3,527,813 cover?
U.S. Patent 3,527,813 was filed on August 25, 1969, and granted on September 15, 1970, assigned to Eli Lilly and Company. The patent relates to a class of pharmaceutical compounds with potential therapeutic applications, notably for central nervous system disorders.
Patent Claims and Scope
Main Claims Overview
The patent's claim set primarily covers:
- Chemical structures: Specifically, 4-phenyl-4-hydroxybutyl derivatives of certain amines.
- Pharmacological activity: The compounds are claimed to exhibit calming, sedative, or anti-anxiety effects.
- Methods of synthesis: Process claims describe procedures to produce these compounds.
Claim Details
- Claim 1: Describes a chemical compound with a core structure comprising a 4-phenyl-4-hydroxybutyl moiety attached to amine groups, where various substituents are specified.
- Dependent Claims (2-6): Detail variations in substituents, including different benzene ring substituents and different amine groups, refining the scope.
- Method claims: Cover synthesis processes, involving steps like reacting phenylketones with suitable reagents under specific conditions.
Scope Analysis
The patent's scope focuses on a chemical class of compounds with a specific backbone, and a particular method of synthesis. It broadly covers derivatives with minor structural modifications, provided they fall within the core chemical framework.
Patent Landscape Context
Prior Art and Patent Family
- Precedent references: Prior art such as earlier phenyl derivatives and sedative compounds predates this patent, influencing scope boundaries.
- Patent family: Other patents share similar chemical classes, including international filings (EP, JP) related to the same or similar compounds.
- Related patents: A review reveals a patent portfolio surrounding benzodiazepine-like compounds, with overlapping structures and therapeutic indications.
Competitor and Market Landscape
- Major players: Eli Lilly's patent regions expand into materials used in sedative-hypnotics, overlapping with benzodiazepine patents held by companies like Roche and Upjohn.
- Patent expiration: The patent expired in 1987, allowing generic synthesis and market entry.
Innovation and Freedom-to-Operate
- The main innovation involved specific structural claims not wholly anticipated by prior art, providing a degree of patent strength within its narrower claims.
- However, the broadest claims may face potential challenges due to prior art references disclosing similar phenyl derivatives.
Key Legal and Technical Considerations
- The patent's claim breadth is limited to a defined chemical structure and specific synthesis methods.
- The narrower dependent claims enhance enforceability, but the core claim's scope is susceptible to invalidation if prior art shows similar compounds existed before 1970.
- The patent's expiration opens freedom-to-operate.
Summary of Patent Landscape
| Aspect |
Details |
| Patent filing date |
August 25, 1969 |
| Issue date |
September 15, 1970 |
| Expiry |
September 15, 1987 |
| Assignee |
Eli Lilly and Company |
| Key claims |
Chemical structure with phenyl and hydroxybutyl groups, synthesis methods |
| Related patents |
Fragmented across several jurisdictions, covering similar derivatives |
| Patent strength |
Narrower dependent claims reinforce enforceability, broad main claim is vulnerable to prior art challenges |
Final assessment
The patent covers a specific chemical class with promising pharmacological activity, but its scope is limited by prior art and narrow claims filed in 1969. The patent era has already expired, leaving open market access for similar compounds.
Key Takeaways
- U.S. Patent 3,527,813 claims a specific chemical class of sedative compounds with defined structures and synthesis methods.
- Its scope is constrained to those structures, with narrow claims supported by specific process steps.
- The patent landscape includes overlapping prior art on phenyl derivatives, affecting enforceability.
- The patent expired in 1987, allowing competitors unrestricted use of similar compounds.
- Companies developing related drugs must consider both the core chemical framework and related prior art when designing new compounds.
FAQs
1. How broad are the claims of U.S. Patent 3,527,813?
The claims are narrow, covering specific phenyl-phenylhydroxybutyl derivatives and their synthesis methods. They do not broadly claim all phenyl derivatives with similar activity.
2. Can similar compounds be developed now?
Yes, the patent expired in 1987, removing patent barriers to developing or commercializing similar chemical entities.
3. What is the relevance of prior art to this patent?
Prior art disclosed similar phenyl derivatives and sedative compounds existing before 1970, which could have limited the patent's enforceability and originality.
4. Are there ongoing patents related to these compounds?
No active patents cover this chemical class since the original patent expired over three decades ago, though newer innovations might be protected under subsequent patent filings.
5. How should a company approach patenting similar compounds today?
Focus on structural modifications that differ significantly from the patented compounds, and consider novel synthesis methods or specific therapeutic indications to establish patentability.
References
- Patent No. 3,527,813. (1970). U.S. Patent and Trademark Office.
- Smith, J., & Lee, D. (1980). Benzodiazepine derivatives and related compounds. Journal of Medicinal Chemistry, 23(4), 455-462.
- Williams, P., & Thomas, G. (1975). Overview of sedative-hypnotic drug patents. Pharmaceutical Patent Law Report, 17(2), 134-142.
More… ↓
⤷ Start Trial
|
